Immune Response of a Heterologous mRNA-1273 Second-Dose Immunization after a First Dose of ChadOx1 against SARS-CoV-2: A Cross-Sectional Study.
COVID-19
antibody response
cross-sectional study
heterologous
spike protein
vaccines
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
02 Aug 2022
02 Aug 2022
Historique:
received:
30
06
2022
revised:
29
07
2022
accepted:
30
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Heterologous vaccination regimens could contribute to broadening vaccination coverage. To date, there is little evidence on the effectiveness of a combination of adenoviral COVID-19 vaccines with a second dose of mRNA vaccines. This study aims to evaluate the antibody response to the SARS-CoV-2 spike protein 25 weeks after vaccination with mRNA-1273 after a first dose of ChAdOx1. A cross-sectional study was conducted collecting sociodemographic data, clinical characteristics, and serological data from among the general population. Antibody levels were expressed as binding antibody units (BAU) per mL (cutoff = 33.8 BAU/mL). Linear regression models were used to assess the relationship between the subjects' characteristics and anti-SARS-CoV-2 antibody levels. A total of 229 participants were followed up after a median time of 173 days. The overall anti-SARS-CoV-2 IgG antibody titer was 729.0 BAU/mL. The multivariable analysis showed that the only factor associated with anti-SARS-CoV-2 IgG levels was the BMI (
Identifiants
pubmed: 36016129
pii: vaccines10081241
doi: 10.3390/vaccines10081241
pmc: PMC9416710
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Mol Sci. 2020 Aug 16;21(16):
pubmed: 32824322
EBioMedicine. 2022 Jan;75:103761
pubmed: 34929493
Lancet. 2021 Jul 10;398(10295):121-130
pubmed: 34181880
Vaccines (Basel). 2022 Mar 25;10(4):
pubmed: 35455261
Front Immunol. 2021 Sep 24;12:753319
pubmed: 34691071
Lancet. 2021 May 29;397(10289):2043-2046
pubmed: 33991480
N Engl J Med. 2021 Sep 9;385(11):1049-1051
pubmed: 34260850
Vaccines (Basel). 2021 Aug 18;9(8):
pubmed: 34452043
J Infect. 2022 May;84(5):692-700
pubmed: 35131335
Lancet Respir Med. 2021 Nov;9(11):1255-1265
pubmed: 34391547
Vaccine. 1997 Jul;15(10):1157-61
pubmed: 9269062
Vaccine. 2022 Mar 8;40(11):1634-1642
pubmed: 33678455
Clin Chim Acta. 2021 Dec;523:201-204
pubmed: 34599902
Vaccine. 2006 Jun 29;24(26):5509-15
pubmed: 16725234
J Travel Med. 2022 May 31;29(3):
pubmed: 34918097
Clin Microbiol Infect. 2018 Jan;24(1):24-28
pubmed: 28232162
Nature. 2021 Dec;600(7890):701-706
pubmed: 34673755
Nutr Metab Cardiovasc Dis. 2019 Apr;29(4):367-377
pubmed: 30795994
Curr Opin Immunol. 2009 Jun;21(3):346-51
pubmed: 19500964
Front Immunol. 2018 May 16;9:1055
pubmed: 29868016
Vaccines (Basel). 2022 Mar 18;10(3):
pubmed: 35335105
BMJ. 2021 Nov 17;375:e068302
pubmed: 34789505
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
Vaccines (Basel). 2021 Jun 22;9(7):
pubmed: 34206312
Nat Med. 2021 Sep;27(9):1530-1535
pubmed: 34312554
JAMA. 2009 Nov 4;302(17):1896-902
pubmed: 19887665
J Infect Dis. 2019 Apr 8;219(8):1187-1197
pubmed: 30407513
Hum Immunol. 2012 May;73(5):480-5
pubmed: 22426256
Int J Antimicrob Agents. 2020 Aug;56(2):106054
pubmed: 32534188
Clin Exp Med. 2022 Aug;22(3):477-485
pubmed: 34741188
Vaccines (Basel). 2022 Jan 20;10(2):
pubmed: 35214613
Obesity (Silver Spring). 2022 May;30(5):999-1003
pubmed: 35226399
PLoS Med. 2021 Dec 17;18(12):e1003874
pubmed: 34919548
Lancet. 2021 Jan 30;397(10272):355-357
pubmed: 33453149
EClinicalMedicine. 2021 Jun;36:100928
pubmed: 34109307